Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 19 clinical trials
Depleted Donor Stem Cell Transplant in Children and Adults With Fanconi Anemia After Being Conditioned With a Regimen Containing JSP191

The objective of this clinical trial is to develop a cell therapy for Fanconi Anemia which enables enhanced donor hematopoietic and immune reconstitution with decreased toxicity by transplanting depleted stem cells from a donor after using an experimental treatment called JSP-191 as a part of conditioning. This experimental treatment will …

anemia
neutrophil count
chromosome abnormalities
chromosome breakage
rabbit atg
  • 0 views
  • 21 Mar, 2022
  • 1 location
Eltrombopag for People With Fanconi Anemia

Background Fanconi anemia is a genetic disease. Some people with it have reduced blood cell counts. This means their bone marrow no longer works properly. These people may need blood transfusions for anemia (low red blood cells) or low platelet counts or bleeding. Researchers want to see if a new …

anemia
neutrophil count
cytopenia
chromosome breakage
eltrombopag
  • 166 views
  • 01 Jul, 2022
  • 1 location
Lentiviral-mediated Gene Therapy for Pediatric Patients With Fanconi Anemia Subtype A

> Hematopoietic stem cells from mobilized peripheral blood of patients with FA-A will be transduced ex vivo (outside the body) with a lentiviral vector carrying the FANCA gene. After transduction, the corrected

  • 2 views
  • 16 Feb, 2022
Gene Therapy for Fanconi Anemia, Complementation Group A

from mobilized peripheral blood of patients with FA-A will be transduced ex vivo (outside the body) with a lentiviral vector carrying the FANCA gene. After transduction, the corrected stem cells will

  • 1 views
  • 25 Feb, 2022
  • 1 location
Quercetin Chemoprevention for Squamous Cell Carcinoma in Patients With Fanconi Anemia

Fanconi anemia (FA) is an autosomal recessive disease characterized by progressive bone marrow failure, variable congenital abnormalities and a predisposition to malignancy, particularly acute myeloid leukemia (AML) and squamous cell carcinoma (SCC). Improved transplant outcomes are modifying the natural history of Fanconi Anemia. Improved transplant survival, no radiation exposure, and …

anemia
chemotherapy regimen
quercetin
myeloid leukemia
cancer
  • 24 views
  • 25 Mar, 2022
  • 1 location
T Cell Receptor α/β TCD HCT in Patients With Fanconi Anemia

This is a phase II trial of T cell receptor alpha/beta depletion (/ TCD) hematopoietic cell transplantation (HCT) transplantation in patients with Fanconi anemia (FA) to eliminate the need for routine graft-versus-host disease (GVHD) immune suppression leading to earlier immune recovery and potentially a reduction in the risk of severe …

stem cell transplantation
aplastic anemia
karnofsky performance status
growth factors
fludarabine
  • 26 views
  • 01 Feb, 2022
  • 1 location
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy (RAFA)

The purpose of this study is to determine whether the use of lower doses of busulfan and the elimination of cyclosporine will further reduce transplant-related side effects for patients with Fanconi Anemia (FA). Patients will undergo a transplant utilizing mis-matched related or matched unrelated donors following a preparative regimen of …

stem cell transplantation
rabbit atg
fludarabine
antithymocyte globulin
cyclosporine
  • 76 views
  • 21 Apr, 2022
  • 2 locations
Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects

This phase II trial studies how well niraparib, when given before surgery, works in treating patients with high risk prostate cancer that has not spread to other parts of the body (localized) and alterations in deoxyribonucleic acid (DNA) repair pathways. Niraparib may stop the growth of tumor cells by blocking …

niraparib
dna damage
vasectomy
absolute neutrophil count
fancl
  • 6 views
  • 21 Mar, 2022
  • 1 location
Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors

The aim of this single-arm phase 2 clinical trial is to evaluate the anti-cancer activity of Talazoparib (also known as BMN 673) in patients with advanced breast cancer with specific genetic or tumor genomic alterations. Patients with either triple-negative or HER2-negative breast cancer are eligible.

mammogram
blood transfusion
advanced breast cancer
estrogen
talazoparib
  • 5 views
  • 08 Sep, 2021
  • 1 location
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.

The purpose of this study is to assess the safety, tolerability and preliminary efficacy of CYH33 in combination with olaprib in patients with DDR gene mutations and/or PIK3CA mutations, in patients who have progressed on prior PARP inhibitor, and in patients with recurrent high grade serous ovarian, fallopian tube, or …

PIK3CA
cancer of the ovary
olaparib
measurable disease
cancer antigen 125
  • 5 views
  • 19 Feb, 2021
  • 1 location